Singapore, Nov. 5 -- Takeda Pharmaceutical Company Limited has announced that it has entered into an agreement to divest a portfolio of select products to STADA Arzneimittel AG, an international pharmaceutical company, for a total value of $660 million. The portfolio includes over-the-counter (OTC) and prescription pharmaceutical products exclusively in Russia, Georgia, and a number of countries from within the Commonwealth of Independent States, which form part of Takeda's Growth & Emerging Markets Business Unit.

This is Takeda's fourth divestment transaction in the past six months that contributes to the Company's goal to divest approximately $10 billion in non-core assets to focus on its five key business areas and commitment to accel...